Список проголосовавших за комментарий "<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Ionis Pharma (<strong>IONS </strong>+20.31%) and Biogen (BIIB) announce Spinraza meets primary endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy</li><li>ChemoCentryx (<strong>CCXI </strong>+8.72%) announces presentations of 'positive' results from the Phase II CLEAR and CLASSIC trials of CCX168 at Kidney Week and the ACR 2016 meeting</li><li>Versartis (<strong>VSAR </strong>+6.04%) presents safety, efficacy, and IGF-I data from somavaratan treatment in the combined Phase 2a and ongoing VISTA long-term safety study for pediatric GHD</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>InfuSystem (<strong>INFU </strong>-4.7%) concludes that various prior financial statements should no longer be relied upon</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Amicus Therapeutics (<strong>FOLD </strong>+16.12%) misses by $0.02; updates anticipated milestones</li><li>Horizon Pharma (<strong>HZNP </strong>+15.55%) beats by $0.08, reports revs in-line; reaffirms FY16 revs guidance</li><li>BioCryst Pharma (<strong>BCRX </strong>+11.51%) beats by $0.10, beats on revs; updates financial guidance & provides a corporate update</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>Concordia (<strong>CXRX </strong>-36.36%) misses by $0.33, misses on revs; suspends guidance</li><li>Nobilis Health (<strong>HLTH </strong>-13.33%) misses by $0.10, beats on revs; reaffirms FY16 revs guidance</li><li>Aurinia Pharma (<strong>AUPH </strong>-6.67%) misses by $0.06</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>TherapeuticsMD (<strong>TXMD </strong>+11.43%) resumed with a Buy at Guggenheim</li><li>Celldex Therapeutics (<strong>CLDX </strong>+7.12%) Aegis Capital Initiated Coverage: BUY</li><li>Alder BioPharma (<strong>ALDR </strong>+7.25%) Aegis Capital Initiated Coverage: BUY</li><li>Premier (<strong>PINC </strong>-4.61%) downgraded to Underperform from Buy at BofA/Merrill</li></ul>"